CEL-SCI Corp. (NYSE: CVM) Starts Presentation at Dawson James Small Cap Growth Conference
CEL-SCI (NYSE: CVM) is at the forefront in the research and development of products for the treatment of cancer, autoimmune and infectious diseases. CEL-SCI believes that boosting a patient's immune system while still intact should provide the greatest possible impact on survival. The company's core capabilities include drug discovery, research, development and manufacturing of complex biological substances. CEL-SCI's phase 3 study is the largest phase 3 study in the world for the treatment of head and neck cancer, and after 8.5 years is very close to completion. Multikine, CEL-SCI's lead investigational therapy, is a potential therapeutic agent directed at enabling…